Haleon to sell non-US nicotine replacement therapy portfolio to Dr. Reddy’s Laboratories
Haleon plc, a prominent player in the global healthcare market, has reached an agreement to sell its nicotine replacement therapy (NRT) business outside of the United States to Dr. Reddy’s Laboratories SA, a subsidiary of Dr. Reddy’s Laboratories Limited. The deal, valued at £500 million, marks a strategic shift for Haleon, allowing it to streamline […]